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ABSTRACT Sepsis has become a major health issue, with more patients dying in
hospitals due to sepsis related complications. The pathogenesis of sepsis is
complex and involves multiple aspects of the interaction between the
infecting microorganisms and the host. Sepsis is fundamentally an
inflammatory disease mediated by the activation of the innate immune
system. In the case, sepsis is an unbalanced (proinflammatory and anti-
inflammatory), dysregulated response, the localized process goes out of
control and becomes systemic contribute to diminished oxygen delivery. The
process also leads to decreased hemodynamic stability, hyperglycemia and
ultimately, multi organ dysfunction syndrome and death in septic shock. The
use of corticosteroid hydrocortisone as adjunctive therapy is still debating
due to the lack of supporting study and differences result among the studies.
INTRODUCTION
Sepsis was defined as the
systemic inflammatory response
syndrome (SIRS) caused by infection.
Shock septic is sepsis in which
circulatory, metabolic, and cellular
disorders are so severe   that they
significantly increase mortality. The
prevalence of sepsis and septic shock is
steadily growing globally. Estimates of
the incidence of sepsis vary widely due to
differences in case ascertainment. Sepsis
was present in more than half of
hospitalizations ending in death or
terminal discharge to hospice in this
cohort of patients from 6 US hospitals,
and was the immediate cause of death in
most of these cases. However, most
underlying causes of death were
associated with severe chronic
comorbidities. One in 8 sepsis-associated
deaths was potentially preventable
through better hospital-based care, but
only 1 in 25 sepsis-associated deaths was
judged definitely or moderately
preventable (Rhee et al. 2019)
The pathophysiology of sepsis is
incompletely understood. There appears
to be inappropriate regulation of normal
physiological reactions to infection, both
pro-inflammatory and anti-inflammatory,
resulting in life-threatening organ
dysfunction. The most severe form of
sepsis is septic shock, a state of
circulatory failure that occurs in a subset
of patients with sepsis in whom
circulatory, cellular and metabolic
abnormalities are associated with an
066 SAKURA MUHAMMAD TOLA
increased risk of death. The diagnosis of
septic shock requires the presence of
sepsis and hypotension requiring
vasopressor therapy to maintain mean
arterial pressure (MAP) 65 mmHg or
greater and a serum lactate of greater than
2 mmol/L despite adequate fluid
resuscitation. In settings where lactate
measurement   is not available, other
indices of tissue hypoperfusion, such as
oliguria, altered mental status and
delayed capillary refill, may be used
instead. While hyperlactaemia is not a
specific sign of sepsis and is not part of
the definition of sepsis, it is a valuable
marker of disease severity and remains an
important component of many effective
screening programmes and treatment
algorithms (Thompson et al. 2018)
The treatment of sepsis should be
based on the understanding of its
pathogenesis. The pathogenesis of sepsis
is not fully understood. Bacteria from
external or local sources enter
bloodstream causing bacteremia. Taking
into account that phagocytosis in the
bloodstream is impossible, blood humoral
bactericidal factors and erythrocytes are
probably the main antibacterial forces in
the blood circulation. The humoral
factors are more effective against bacteria
from external source. Bacteria from a
local source may be more resistant to the
bactericidal action of plasma because
blood humoral factors also present in the
tissues and before entering the
bloodstream from the tissues, bacteria
should have overcome their action.
Treating sepsis is a multidisciplinary task.
Early recognition and commencing initial
steps of resuscitation are inevitable to
give the best possible chance for survival,
which has to be started on the primary
care level: outside the hospital, in the
emergency department or on the wards.
In the absence of adequate initial
management, providing even the highest
level of intensive care would be in vain.
Pathophysiologic mechanisms in septic
shock
The pathogenesis of sepsis is
complex and involves multiple aspects of
the interaction between the infecting
microorganisms and the host. The
recognition of pathogens and the
resulting cellular activation are
fundamental for infection control.
Paradoxically, the host inflammatory
response is also the substrate for the
pathophysiological changes in sepsis.
Inflammation can cause dysfunction of
the vascular endothelium, accompanied
by cell death and loss of barrier integrity,
giving rise to subcutaneous and body-
cavity edema. In addition, mitochondrial
damage caused by oxidative stress and
other mechanisms impairs cellular
oxygen use. Moreover, injured
mitochondria release alarmins into the
extracellular environment, including
mitochondrial DNA and formyl peptides,
which can activate neutrophils and cause
further tissue injury (King et al., 2014)
Under normal conditions,
bacterial entry into a sterile field activates
resident macrophages to contain the
initial infection. Oftentimes, the initial
infectious insult is too great for resident
macrophages alone to eradicate all
bacteria. However, regardless of whether
or not the primary infection is contained,
macrophages, of the M1 phenotype,
initiate the immune system response by
releasing inflammatory mediators such as
tumor necrosis factor (TNF), interleukin-
1b (IL-1b), IL-6 and CXCL-8. This
signals endothelial cells to upregulate
adhesion molecules and begin the
recruitment of other inflammatory cells
including the phagocytic cells
(polymorphonuclear cells, monocytes and
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macrophages) of the innate immune
response and lymphocytes of the adaptive
immune response frequently become
dysfunctional in sepsis to help control the
infection. Neutrophils also have a role in
cell recruitment signaling (King et al.,
2014; Hotchkiss, et al., 2017).
Activation of these various
receptors during infection is fundamental
for the recognition of a wide range of
microorganisms and result in
complementary, synergistic, or
antagonistic effects, thus modulating
innate and adaptive immunity. The
release of inflammatory mediators by
innate immune cells upon pathogen
recognition resulting in the activation of
coagulation, vasodilation, endothelial
leakage, rolling and extravasation of
neutrophils and inflammatory mediators
to the extravascular space, underscores
the pathophysiology of organ
dysfunctions and hypotension during
sepsis. Of paramount importance, the
inflammatory response triggers
procoagulant factors, while natural
anticoagulant factors, such as activated
protein C, anti-thrombin, and tissue factor
inhibitors, are decreased in septic patients,
resulting in a procoagulant state with
multiple microthrombi and the
obstruction of small vessels, which
ultimately leads to intravascular
disseminated coagulation and
complement system, resulting in local
ischemica, which impairs cellular
respiration (Salomao et al., 2019).
However, in the case of an unbalanced
(proinflammatory and anti-inflammatory),
dysregulated (maturation and
proliferation) response, the localized
process goes out of control and becomes
systemic, in other words the disease of
the whole body; hence, it gives way for
impairing the function of distant vital
organs. This makes the clinical
manifestation of critical illness so similar
regardless of the insult (Salomao et al.,
201; Laszlo et al., 2015). The overall end
result of these process are global tissue
hypoxia in which the systemic oxygen
delivery is insufficient to meet the
oxygen demands of the body. This leads
to decreased myocardial contractility,
decreased systemic vascular resistance,
hypotension, metabolic acidosis,
hyperglycemia and ultimately, multi
organ dysfunction syndrome and death.
Diagnosis of Septic Shock
The diagnosis of septic shock is
multifactorial and includes: an initial
assessment of the etiology and clinical
signs and symptoms, of the
hemodynamic parameters, of the cellular
changes, and of the grade of tissue
dysfunction. Some parameters of the
definition of shock have not been clearly
defined, e.g. adequate fluid resuscitation,
no vasopressors, and threshold blood
pressure. Rapid recognition of the
underlying mechanism of shock is of
paramount importance, as the delay in
adequate treatment worsens patient’s
condition. Hemodynamic monitoring
may help explain the patophysiological
phenomena that are characteristic for
septic shock is key principle in the
management of the septic shock patient,
resulting in improved survival outcomes
(Angus et al., 2013). Deteriorating
patients with a raised early warning score
(such as a raised aggregate early warning
score of 5 or above) should therefore be
screened for infection. However,
presently no gold standard to diagnose
sepsis exists. It is fundamental to identify
the signs of systemic inflammation, such
as fever and leukocytosis, which may be
the result of an infection process. Patients
in septic shock present with impaired
myocardial contractility in about 30% of
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cases. Investigations such as a complete
blood count (CBC), urinalysis, blood
cultures, chest X-ray as well as more
sophisticated imaging modalities may
assist in finding the source of infection.
Additional clinical and laboratory
variables may be used to assess the
severity of sepsis, organ dysfunction and
organ hypoperfusion (Angus et al., 2013;
Wadelek et al., 2017; Keeley et al., 2017).
Treatment of Septic Shock
The Surviving Sepsis Campaign,
an international consortium of
professional societies involved in critical
care, treatment of infectious diseases, and
emergency medicine, recently issued the
clinical guidelines for the management of
severe sepsis and septic shock. The
important elements of the guidelines are
organized into two “bundles” of care: an
initial management bundle to be
accomplished within 6 hours after the
patient’s presentation and a management
bundle to be accomplished in the ICU.
Implementation of the bundles is
associated with an improved outcome.
The principles of the initial management
bundle are to provide cardiorespiratory
resuscitation and mitigate the immediate
threats of uncontrolled infection. The
exact components required to optimize
resuscitation, such as the choice and
amount of fluids, appropriate type and
intensity of hemodynamic monitoring,
and role of adjunctive vasoactive agents,
all remain the subject of ongoing debate
and clinical trials. Nonetheless, some
form of resuscitation is considered
essential, and a standardized approach
has been advocated to ensure prompt,
effective management. The initial
management of infection requires
forming a probable diagnosis, obtaining
cultures, and initiating appropriate and
timely empirical antimicrobial therapy
and source control (Angus et al., 2013;
Dellinger et al., 2012).
Pharmacokinetic Profile of
Hydrocortisone
Hydrocortisone is a member of
glucocorticoids group. Gglucocorticoid
activity is determined by a hydroxyl
group at carbon-11 of the steroid
molecule. Cortisone and prednisone are
11-keto compounds, lacking
glucocorticoid activity. They are
converted in the liver to cortisol and
prednisolone respectively, the
corresponding 11-β hydroxyl compounds.
All glucocorticoid preparations marketed
for topical or local use (like intra-
articular) are 11-β hydroxyl compounds,
obviating the need for biotransformation.
The actions of all corticosteroids are
mediated by interaction of hormone with
corticosteroids receptor, which regulates
gene transcription. Corticosteroids
continue to act inside the cell even after
their disappearance from the circulation,
as the events initiated and the products of
these events (such as specific proteins)
may be present even after disappearance
of corticosteroids from the circulation
(Gupta et al., 2008).
Systemically used glucocorticoid
are classified as short acting, intermediate
acting and long acting based on their
duration of ACTH suppression. They also
differ in their relative glucocorticoid
versus mineralcorticoid potency.
However one must remember that even
those corticosteroids which have low
mineralcorticoid activity (eg.
hydrocortisone) may have
mineralcorticoid effects when used in
high doses. The relative potency of
corticosteroids differ due to their affinity
for the receptor. However, observed
potency is determined by both intrinsic
biologic potency and duration of action.
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There is little correlation between
circulating half life (t1/2) and its potency.
Similarly little correlation exist between
t1/2 and its duration of action (Gupta et al.
2008). The biologic rationale for their use
includes immune modulation, effects
upon cardiovascular tone, and the
treatment of relative corticosteroid
deficiency. The anti-inflammatory effects
of corticosteroids are well established.
Corticosteroids modulate the
transcription of an array of mainly
nuclear factor κB–regulated genes that
contribute to inflammation.The synthesis
of interleukin-1, interleukin-6, and tumor
necrosis factor-α is inhibited, as is
inducible cyclooxygenase 2 and inducible
nitric-oxide synthase. GC decrease
recruitment and function of inflammatory
cells and vascular permeability at the site
of inflammation. They also inhibit
prostaglandin and leucotriene synthesis
by inhibiting the release of arachidonic
acid from the phospholipids. By these
mechanisms, GC protect the organism
from the damage caused by its own
defense reactions and the products of
these reactions during stress (Gupta et al.,
2008).
Corticosteroids also enhance the
vasoconstrictor response to vasopressor
drugs, in particular exogenous
catecholamines. Although the precise
mechanism by which this occurs is not
known, inhibition of cyclooxygenase 2
and inducible nitric-oxide synthase are
likely to play a role. Corticosteroids also
mediate catecholamine release from
neural cells, and this may partly explain
the effect of corticosteroids on the
vasculature. Suppression of
proinflammatory cytokines and improved
circulatory dynamics provide biologic
plausibility that corticosteroids may
reduce mortality through improved tissue
perfusion and metabolic function (Gupta
et al., 2008; Cohen et al., 2019).
The physiological secretory rate
of cortisol in the intact system is
approximately   6 mg/m2/day. The usual
maintainance glucocorticoid dose is
adjusted above this estimated secretory
rate as the bioavailability of cortisol is
reduced by gastric acids and first pass
metabolism in liver. Thus 8-10
mg/m2/day of oral hydrocortisone (HC)
is a reasonable initial starting dose,
though patients with primary adrenal
insufficiency may require slightly higher
doses of 10-12 mg/m2/day. Later on, the
dose may be individualised to avert signs
and symptoms of adrenal insufficiency on
the one hand while avoiding growth
retardation and cushingoid features on the
other. Continuous infusion of
hydrocortisone could hasten the
resolution of septic shock compared to
bolus administration. Earlier initiation
corresponds with a higher probability of
shock reversal. Tapering strategy is
unnecessary (Ibarra-Estrada et al., 2017).
Study Related to the role of
Corticosteroid Hydrocortisone in
Septic Patients
There is an established biological
rationale for the administration of
adjunctive corticosteroids in the
management of patients with septic shock.
Corticosteroids act through two
mechanisms: immune modulation and
cardiovascular modulation.
The Surviving Sepsis Campaign
(SSC) in 2016 recommended that low-
dose hydrocortisone should not be used
as a routine adjunctive therapy in septic
shock if adequate fluid resuscitation and
vasopressor therapy restore
hemodynamic stability. In patients who
do not reach this goal, 200 mg of
hydrocortisone using continuous infusion
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per day should be given. The Surviving
Sepsis Campaign recommended to
administer hydrocortisone as continuous
infusion to better prevent hyperglycemia.
Rhodes et al., 2017 Nevertheless, the
patterns in clinical practice remain widely
heterogeneous because of differing
interpretations of the definition of poor
responsiveness of shock to fluid and
vasopressor therapy, discrepancy
between clinicians interpretation of
guidelines, discrepancy in clinical
practice, and unfamiliarity with existing
evidence
The European multicenter
(CORTICUS) study (n = 499), which
evaluated the role of 200 mg of
hydrocortisone/day versus placebo in
patients with septic shock, did not
demonstrate any beneficial effect on
overall mortality (34% vs. 31%; P =
0.51) or in the subgroups of corticotropin
“responders” or “nonresponders” and
reported more episodes of superinfection
in the patients who received steroids.18
The CORTICUS trial had planned on a
target enrollment of 800 patients to detect
a 10% reduction in mortality in patients
who were nonresponders. The study was
stopped prematurely when lower than
expected recruitment resulted in
termination of funding and expiry of the
study drug supply. As a result, the trial
was significantly underpowered to detect
a clinically important treatment effect
(Sprung et al., 2008). Lian et al
conducted study meta-analysis to
reevaluate the benefits and risks of
corticosteroid treatment in adult patients
with septic shock. Twenty-one RCTs
were identified and analyzed. Patients
treated with corticosteroid had a 7%
reduction in relative risk in 28-day all-
cause mortality compared to controls (RR
0.93, 95% CI 0.88 to 0.99). However,
there were no significant differences for
the intensive care unit (ICU) mortality
(RR 0.97, 95% CI 0.86 to 1.09) or in-
hospital mortality (RR 1.01, 95% CI 0.92
to 1.11). Corticosteroids shortened the
length of ICU stay by 1.04 days (RR -
1.04, 95% CI -1.72 to -0.36) and the
length of hospital stay by 2.49 days (RR -
2.49, 95% CI -4.96 to -0.02).
Corticosteroids increased the risk of
hyperglycemia (RR 1.11, 95% CI 1.06 to
1.16) but not gastroduodenal bleeding
(RR 1.06, 95% CI 0.82 to 1.37) or
superinfection (RR 1.04, 95% CI 0.94 to
1.15). However, some date on secondary
outcomes were unavailable because they
were not measured or not reported in the
included studies which may cause a lack
of power or selective outcome reporting.
The information size was calculated at
10044 patients. Trial sequential analysis
showed that the meta-analysis was
conclusive and the risk of type 2 error
was minimal. The study concluded that
corticosteroids are likely to be effective
in reducing 28-day mortality and
attenuating septic shock without
increasing the rate of life-threatening
complications. TSA showed that the risk
of type II error in this meta-analysis was
minimal and the result was conclusive
(Lian et al. 2019).
The adrenal trial randomized
3,800 patients with septic shock in 69
intensive care units from five countries to
either 200mg of hydrocortisone
administered by infusion or matched
placebo. There was no statistically signif-
icant difference in the primary outcome
of 90-day mortality between the two
groups (27.9% vs. 28.8%; OR, 0.95; CI,
0.82 to 1.1; P = 0.5). However, some of
the secondary outcomes were improved
in the hydrocortisone group; patients
assigned to the hydrocortisone group had
earlier shock reversal, faster liberation
from mechanical ventilation, reduced
CORTICOSTEROID IN SEPTIC SHOCK: ADVANTAGE OR DISADVANTAGE? 071
frequency of blood transfusion, and
earlier discharge from intensive care.
There were no significant differences
between the treatment groups with
respect to 28-day mortality, the rate of
recurrence of shock, recurrence of
mechanical ventilation, duration and rate
of use of renal replacement therapy, time
to hospital discharge, the rate of
development of new-onset bacteremia or
fungemia, and 6-month mortality
(Venkatesh et al., 2018).
The second double-blind RCT
(APROCCHSS) by Djillali Annane
investigated the combination of
intravenous bolus hydrocortisone (50 mg
four times a day) and oral fludrocortisone
(50 µg per day) in 1,241 patients. For
inclusion in the study the use of
vasopressors (norepinephrine,
epinephrine) was required at a minimum
dose of ≥0.25 µg per kilogram of body
weight per minute or ≥1 mg per hour for
at least 6 hours to maintain a systolic
blood pressure of at least 90 mmHg or a
mean blood pressure of at least 65 mmHg.
The patients was divided into the groups
receiving Hydrocortisone 50 mg IV every
6 hours and fludrocortisone 50 mcg NG
daily for 7 days without taper and the
group receiving placebo. In this study, a
significant reduction in death of any
cause at day 90 was reported with the use
of steroids (43.0% vs. 49.1%, P=0.03). In
addition, mortality was reduced at ICU
discharge (35.4% vs. 41.0%, P=0.04),
hospital discharge (39.0% vs. 45.3%,
P=0.02), and day 180 (46.6% vs. 52.5%,
P=0.04). Secondary endpoints such as
vasopressor-free days and organ-failure-
free days to day 28 were significantly
higher in patients treated with the two
steroids, as was the time to weaning from
mechanical ventilation to day 90 (Annane
et al., 2018).
Overall corticosteroids are
typically inexpensive and widely
available. The impact of corticosteroids
on the overall costs to patients and to
health systems is uncertain and would be
driven mostly by ICU and hospital
lengths of stay or prolonged periods of
rehabilitation.  Beside that corticosteroid
treatment is associated with numerous
adverse effects, including metabolic
derangements, gastrointestinal bleeding,
neuromuscular weakness, and
immunosuppression. A tapering strategy
for cessation of corticosteroids has
previously been advocated because of the
observation of an increase in
inflammatory mediators upon abrupt
cessation of treatment.
CONCLUSION
Septic shock is an emergency
state that requires a rapid diagnostic
process that helps to discover signs and
symptoms and the etiology of the shock.
The role of adjunctive corticosteroid in
septic shock patient remains controversial.
Although some studies showed the
administration of hydrocortisone could
improve the survival rate of the patients.
Clinical questions remain over the
optimum duration of treatment and the
role of corticosteroids in relapsing shock.
The use of hydrocortisone must be justify
by the clinician based on the patient
condition. More studies are needed to
clarify and intensify the role of
corticosteroid and the impact of
corticosteroid therapy on healthcare cost
in septic patient in the intensive care units.
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